Latham Advises Quotient Sciences on Acquisition of Arcinova

London team represents drug development and manufacturing accelerator in acquisition of UK-based contract development and manufacturing organization.

February 09, 2021

Latham & Watkins advised Quotient Sciences, the drug development and manufacturing accelerator, on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization. With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.

The acquisition expands Quotient’s service portfolio and will enable the integration of the drug substance, drug product and clinical testing capabilities all under one organization. Quotient is a portfolio company of private equity firm Permira. As part of the deal, Arcinova’s minority equity partner, BFG, will exit the business, having backed its growth since 2018.

Latham’s deal team was led by London corporate partners Tom Evans and Neil Campbell, with associates Cigi Puthuppally and Zaal Cama. Advice was also provided on regulatory and compliance matters by a cross-border team consisting of Washington, D.C. partner Ben Haas and associate Barrett Tenbarge, and London associates Frances Stocks Allen and Oliver Mobasser; on intellectual property, data privacy and security matters by London partner Deborah Kirk and associate Claudia Sousa; on EHS and ESG matters by London partner Paul Davies and counsel Michael Green; on anti-corruption matters by London counsel Daniel Smith, with associate Bryce Williams; on real estate matters by London counsel Michael Beanland; on finance matters by London associates Ben Wright and Carrie Chen; and on employment matters by London partner Catherine Drinnan with associate Patrick Ritchie.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.